Inpatient Department

The inpatient ward provides space for hospitalization of patients with hematopoietic disorders for the purpose of diagnosis of these conditions and especially their therapy. In cooperation with the complement of the IHBT laboratories, highly specialized examinations are performed, including the latest molecular genetic and cytogenetic methods. Treatment is carried out in accordance with current national and international therapeutic procedures using standard and highly innovative drugs.

The spectrum of our patients consists mainly of:

• Patients with highly malignant hematological malignancies including acute myeloid leukemias (AML), acute lymphoblastic leukemias (ALL), blastic phases of chronic myeloid leukemia (CML) and advanced stages of myelodysplastic syndrome (MDS)
• Patients with early and late complications after hematopoietic cell transplantation
• Patients with congenital or acquired bleeding disorders, including treatment and monitoring of these patients after surgical or dental procedures
• Patients with aplastic anemia or hematopoietic depletion due to other causes, patients with severe forms of hemolytic anemias, and patients with rare red blood cell diseases

The treatment of patients in the inpatient ward is regularly consulted within the working groups for individual haematological diagnoses that are established within the IHBT, such as the working group for acute myeloid leukaemia or the working group for myelodysplastic syndrome. Members or leaders of these groups are often personally involved in the treatment of patients.

The inpatient ward also regularly hosts international clinical and small academic trials, giving inpatients access to the latest experimental drugs or therapeutic approaches.